醋酸卡泊芬净 - CAS:179463-17-3 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	醋酸卡泊芬净热销
英文名称:	Caspofungin acetate
CAS No:	179463-17-3	分子式:	C₅₆H₉₆N₁₀O₁₉	分子量:	1213.42
CAS No:	179463-17-3
分子式:	C₅₆H₉₆N₁₀O₁₉
分子量:	1213.42

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF) 点击下载技术规格说明书(PDF)

C10100 醋酸卡泊芬净 ≥98%(HPLC) (psaitong)

相关产品

包装规格：

5mg 25mg 100mg in glass bottle

溶解性：

溶于水（15mg/mL）和DMSO。

产品描述：

基本信息

产品编号：C10100
产品名称：Caspofungin acetate
CAS:	179463-17-3	储存条件	粉末	-20℃（避光）	四年
分子式：	C56H96N10O19		溶于液体	-80℃（避光）	两年
分子量	1213.42
化学名：	Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-[(10R,12S)-10,12-dimethyl-1-oxotetradecyl]-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-, acetate (1:2)
Solubility (25°C)	体外	DMSO	100mg/mL (82.41mM)
		Ethanol	Insoluble
		Water	100mg/mL (82.41mM)
	体内	现配现用
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	0.8241mL	4.1206mL	8.2412mL
5mM	0.1648mL	0.8241mL	1.6482mL
10mM	0.0824mL	0.4121mL	0.8241mL
50mM	0.0165mL	0.0824mL	0.1648mL

生物活性

产品描述	一种脂肽抗真菌药物,称为棘球蛋白。它通过抑制酶（1→3）-β-D-葡聚糖合成酶起作用，从而干扰真菌细胞壁的完整性。
靶点/IC₅₀	β-1,3-glucan synthase
体内研究	Mice injected with caspofungin at vitreal concentrations from 0.41 to 4.1μM do not have significant alterations in their ERG waveforms, and their retinas have no detectable morphologic changes or loss of cells. At the vitreal concentration of 41 μM,caspofungin reduces the amplitudes of the a-waves, b-waves, and scotopic threshold responses of the ERG and also produces a decrease in the number of cells in the ganglion cell layer. Caspofungin (8mg/kg) or amphotericin B at 1mg/kg given i.p. once daily for 7 days beginning at 30 h after infection resulted in 100% survival through day 28 relative to vehicle control treatment, which results in 100% mortality by day 11 after infectious challenge. Caspofungin reduces recovery of viable Candida from kidney and brain tissues compared to vehicle control treatment on day 5, when control burden peaked. Caspofungin-treated mice dosed with 2mg/kg or greater have significantly lower brain burden than amphotericin-B-treated mice at day 5. Amphotericin B and caspofungin treatment reduce kidney fungal burden by 1.7 log CFU/g and 2.46 to 3.64 log CFU/g, respectively.
特征

推荐实验方法(仅供参考)

动物实验:

Animal Administration

Antifungal therapy is initiated at 30 h after infectious challenge and is given by intraperitoneal (i.p.) injection once daily for 7days. Mice are treated with caspofungin at 1, 2, 4, or 8mg/kg/day, amphotericin B at 1mg/kg/day, or vehicle control (sterile distilled water). Efficacy in this model is assessed in 3 ways: by monitoring survival in a group of 10 animals in each treatment group, by monitoring Candida burden in kidney and brain tissues in a second set of treated animals, and by histologically evaluating the kidneys and brains in a third set of treated animals. Mice are euthanized by CO2 inhalation, and tissues for both culture and histology are sampled at 30h (vehicle-treated control only) and at days 5 (24h after 4th dose), 8 (24h after last dose), 14, 21 (caspofungin-treated only), and 28 after challenge.

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

点击下载核磁/氢谱图谱(PDF)

搜索质检报告(COA)

参考文献 & 客户发表文献